Navigation Links
OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced today that the results of its Phase II combretastatin A4 phosphate (CA4P) clinical trial in myopic macular degeneration (MMD) was presented at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL. The abstract may be viewed at www.arvo.org.

The following are the poster session details: -0-

Poster No.:   1457/B534

Abstract      Phase II Clinical Trial of Intravenous Combretastatin A4

 Title:        Phosphate in Patients With Subfoveal Choroidal

               Neovascular Membranes (CNV) in Pathologic Myopia

Presentation  Monday, May 07, 2007, 8:30 AM -10:15 AM

 Time:

The poster provided additional details from the ZYBRESTAT(TM) CA4P Phase II clinical trial (MMD-213) in Myopic Macular Degeneration, top-line results from which the Company previously announced on February 15, 2007. Based on the positive results from this study, in which 100% of patients met the primary endpoint of maintenance of visual acuity, the Company has held a pre-IND meeting with the FDA regarding topical ophthalmic formulations (eye drops and ocular mini-tabs), is proceeding with development of a topical formulation of ZYBRESTAT(TM), and anticipates filing and IND and initiating clinical studies with the formulation in early 2008.

About the Study (MMD-213):

MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P for treating subfoveal choroidal neovascularization in subjects with pathologic myopia. Subjects were assigned to receive CA4P at doses of 27, 36 or 45 mg/m(2). A total of 23 subjects, 7-8 per arm, were enrolled. All subjects receive
'"/>




Page: 1 2 3

Related medicine technology :

1. OXiGENE Abstracts Published in ASCO Program
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Multiple ... in demyelination, axonal transection, and neurodegeneration. The myelin sheath ... immune system, which targets neurons within the central nervous ... which the damage of the myelin sheath causes disruption ...
(Date:8/29/2014)... Aug. 29, 2014  Pacific Medical Data Solutions is ... website design . The main website, along with the ... company,s new services and content relevant to the medical ... streamlined design, viewers can now better understand how PMDS ... practices and create a more visible platform about medical ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... Orthopedic Soft Tissue Repair Devices Market 2014-2018" report ... are the mass of cells that connect, support, or ... tissues such as tendons, ligaments, cartilage, fascia, and other ... of these tissues with age result in wear and ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... 2011 Brain Plasticity Inc. (BPI), a technology incubator ... that harness the basic principles of brain plasticity to ... disorders, was recently awarded a $2 million grant from ... The grant will fund a two-year clinical trial of ...
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
Cached Medicine Technology:U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 2U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 3New Test to Screen for Glaucoma Damage 2
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- If you have ... more serious treatment later, an expert says. A bunion ... big toe when bone or tissue moves out of place ... untreated, bunions can cause debilitating pain and may require surgery ... at CentraState Medical Center in Freehold, N.J. To prevent ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 A ... hearing wellness solutions, is on its way to the ... the San Diego Convention Center to exhibit and demonstrate ... work in high-noise industrial environments. Etymotic’s safety earphones and ... wearable technology devices at the show. , The ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
Breaking Medicine News(10 mins):Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
... ... with AiRISTA to provide Wi-Fi-based RFID solutions. , ... Sparks, Maryland (PRWEB) September 14, 2009 ... (DCC) to promote, distribute, implement and support AiRISTA,s solutions and technologies ( www.AiRISTA.com ...
... works in different way than standard medicines , SUNDAY, ... people whose high blood pressure cannot be controlled by ... researchers report. , Substantial reductions in blood pressure were ... people who were still hypertensive despite trying three or ...
... ... has been awarded the prestigious Gold certification from Cisco systems for ... The Certification recognizes High Point,s expert level of achievement for advanced ... Data Center. Gold Certified Partners are considered extensions of Cisco,s support ...
... the first ever found to prevent cartilage loss from osteoarthritis ... cartilage that has been lost to osteoarthritis, according to an ... American Society for Bone and Mineral Research in Denver. While ... osteoarthritis that develops following knee injuries, according to the study ...
... say they,ll donate than do, leaving long waits for transplants ... and large say they support the idea of donating some ... lives, reality presents a different picture. , Just 38 percent ... organ and tissue donors, according to a report this year ...
... , FRAMINGHAM, Mass., Sept. 11 Philips Lifeline ... subscribers of its personal emergency response service to alert users of ... is used primarily by seniors living independently in their homes who ... button" worn on the body, users connect to a remote monitoring ...
Cached Medicine News:Health News:AiRISTA's Unified Visibility Solutions Bringing Together Wi-Fi RTLS, And Telemetry Offer Enormous Business Opportunities To Systems Integrators 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 3Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 4Health News:For Organ Donation, Intent and Reality Don't Align 2Health News:For Organ Donation, Intent and Reality Don't Align 3Health News:Lifeline Issues Safety Notice to Subscribers 2
PTC-100 cycler with Hot Bonnet heated lid,holds sixty 0.5ml tubes...
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
Px2 thermal Cycler chassis (requires block). Multiple interchangeable blocks. Gradient capability. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced r...
Custom programming of 3 hot blocks and 1 cold block, 30% reduction in cycling time, Unmatched well-to-well uniformity, No gradient feature...
Medicine Products: